231 related articles for article (PubMed ID: 30660776)
1. Effect of estrous cycle on schizophrenia-like behaviors in MAM exposed rats.
Perez SM; Donegan JJ; Lodge DJ
Behav Brain Res; 2019 Apr; 362():258-265. PubMed ID: 30660776
[TBL] [Abstract][Full Text] [Related]
2. Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam.
Du Y; Grace AA
Int J Neuropsychopharmacol; 2016 Nov; 19(11):. PubMed ID: 27432008
[TBL] [Abstract][Full Text] [Related]
3. Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia.
Perez SM; Chen L; Lodge DJ
Psychoneuroendocrinology; 2014 Sep; 47():88-97. PubMed ID: 25001958
[TBL] [Abstract][Full Text] [Related]
4. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia.
Penschuck S; Flagstad P; Didriksen M; Leist M; Michael-Titus AT
Eur J Neurosci; 2006 Jan; 23(1):279-84. PubMed ID: 16420437
[TBL] [Abstract][Full Text] [Related]
5. The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.
Hradetzky E; Sanderson TM; Tsang TM; Sherwood JL; Fitzjohn SM; Lakics V; Malik N; Schoeffmann S; O'Neill MJ; Cheng TM; Harris LW; Rahmoune H; Guest PC; Sher E; Collingridge GL; Holmes E; Tricklebank MD; Bahn S
Neuropsychopharmacology; 2012 Jan; 37(2):364-77. PubMed ID: 21956444
[TBL] [Abstract][Full Text] [Related]
6. Memory deficits with intact cognitive control in the methylazoxymethanol acetate (MAM) exposure model of neurodevelopmental insult.
O'Reilly KC; Perica MI; Fenton AA
Neurobiol Learn Mem; 2016 Oct; 134 Pt B(Pt B):294-303. PubMed ID: 27485950
[TBL] [Abstract][Full Text] [Related]
7. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
Gill KM; Lodge DJ; Cook JM; Aras S; Grace AA
Neuropsychopharmacology; 2011 Aug; 36(9):1903-11. PubMed ID: 21562483
[TBL] [Abstract][Full Text] [Related]
8. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.
Moore H; Jentsch JD; Ghajarnia M; Geyer MA; Grace AA
Biol Psychiatry; 2006 Aug; 60(3):253-64. PubMed ID: 16581031
[TBL] [Abstract][Full Text] [Related]
9. Adolescent Social Isolation Affects Schizophrenia-Like Behavior in the MAM-E17 Model of Schizophrenia.
Bator E; Latusz J; Głowacka U; Radaszkiewicz A; Mudlaff K; Maćkowiak M
Neurotox Res; 2018 Aug; 34(2):305-323. PubMed ID: 29536265
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.
Perez SM; Aguilar DD; Neary JL; Carless MA; Giuffrida A; Lodge DJ
Neuropsychopharmacology; 2016 Jan; 41(2):477-86. PubMed ID: 26068729
[TBL] [Abstract][Full Text] [Related]
11. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.
Gomes FV; Guimarães FS; Grace AA
Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522381
[TBL] [Abstract][Full Text] [Related]
12. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.
Lodge DJ; Behrens MM; Grace AA
J Neurosci; 2009 Feb; 29(8):2344-54. PubMed ID: 19244511
[TBL] [Abstract][Full Text] [Related]
13. Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17.
Léna I; Chessel A; Le Pen G; Krebs MO; Garcia R
Psychopharmacology (Berl); 2007 Jun; 192(3):373-83. PubMed ID: 17279373
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid (VPA) reduces sensorimotor gating deficits and HDAC2 overexpression in the MAM animal model of schizophrenia.
Bator E; Latusz J; Radaszkiewicz A; Wędzony K; Maćkowiak M
Pharmacol Rep; 2015 Dec; 67(6):1124-9. PubMed ID: 26481530
[TBL] [Abstract][Full Text] [Related]
15. Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Takahashi K; Nakagawasai O; Sakuma W; Nemoto W; Odaira T; Lin JR; Onogi H; Srivastava LK; Tan-No K
Neuropharmacology; 2019 May; 150():1-14. PubMed ID: 30831160
[TBL] [Abstract][Full Text] [Related]
16. Impaired contextual fear-conditioning in MAM rodent model of schizophrenia.
Gill KM; Miller SA; Grace AA
Schizophr Res; 2018 May; 195():343-352. PubMed ID: 28927551
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities in behaviour, histology and prefrontal cortical gene expression profiles relevant to schizophrenia in embryonic day 17 MAM-Exposed C57BL/6 mice.
Huo C; Liu X; Zhao J; Zhao T; Huang H; Ye H
Neuropharmacology; 2018 Sep; 140():287-301. PubMed ID: 30056124
[TBL] [Abstract][Full Text] [Related]
18. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.
Lodge DJ; Grace AA
Behav Brain Res; 2009 Dec; 204(2):306-12. PubMed ID: 19716984
[TBL] [Abstract][Full Text] [Related]
19. Effects of prenatal methylazoxymethanol acetate (MAM) treatment in rats on water maze performance.
Leng A; Jongen-Rêlo AL; Pothuizen HH; Feldon J
Behav Brain Res; 2005 Jun; 161(2):291-8. PubMed ID: 15922056
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
Albeely AM; Williams OOF; Blight CR; Thériault RK; Perreault ML
Schizophr Res; 2024 May; 267():451-461. PubMed ID: 38643726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
